Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66-84 years in Japan and Shiga prefecture.

IF 1.5 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-28 DOI:10.1080/14737167.2025.2519755

Tomoyuki Suzuki, Yoko Hirano, Kazumasa Kamei, Kayoko Miyata, Masahiro Kusama, Piotr Karwala, Camille Moyon, Catriona Crossan, Shuhei Ito, Jeffrey Vietri, Fumihiko Kakuno

{"title":"Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66-84 years in Japan and Shiga prefecture.","authors":"Tomoyuki Suzuki, Yoko Hirano, Kazumasa Kamei, Kayoko Miyata, Masahiro Kusama, Piotr Karwala, Camille Moyon, Catriona Crossan, Shuhei Ito, Jeffrey Vietri, Fumihiko Kakuno","doi":"10.1080/14737167.2025.2519755","DOIUrl":null,"url":null,"abstract":"Background: The Japanese National Immunization Program against pneumococcal disease (PD) includes 23-valent pneumococcal polysaccharide vaccine (PPSV23) but does not provide vaccination for adults aged ≥66 years. We evaluated the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) in adults aged 66-84 years with no history of PPSV23 vaccination in Japan and assessed the potential economic and health impact of introducing PCV20 on the local government (specifically, Shiga prefecture).Research design and methods: Using a Markov model, we assessed lifetime costs, quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by PD.Results: In national-level analysis, PCV20 was cost-effective compared with no vaccination under incremental cost-effectiveness ratio threshold of Japanese yen (JPY) 5,000,000/QALY, i.e. JPY1,677,401/QALY and JPY1,351,811/QALY from payer and societal perspectives, respectively. PCV20 was dominant (less costly and more effective) compared with PPSV23. In local-level analysis, the introduction of PCV20 required initial costs but resulted in greater cost savings related to medical expenses (-JPY424 and -JPY430 per person) and nursing care (-JPY560 and -JPY575 per person) compared to PPSV23 and no vaccination, respectively.Conclusions: PCV20 is cost-effective compared with PPSV23 and no vaccination in adults aged 66-84 years, which could reduce the future healthcare burden in Japan.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-14"},"PeriodicalIF":1.5000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2519755","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The Japanese National Immunization Program against pneumococcal disease (PD) includes 23-valent pneumococcal polysaccharide vaccine (PPSV23) but does not provide vaccination for adults aged ≥66 years. We evaluated the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) in adults aged 66-84 years with no history of PPSV23 vaccination in Japan and assessed the potential economic and health impact of introducing PCV20 on the local government (specifically, Shiga prefecture).

Research design and methods: Using a Markov model, we assessed lifetime costs, quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by PD.

Results: In national-level analysis, PCV20 was cost-effective compared with no vaccination under incremental cost-effectiveness ratio threshold of Japanese yen (JPY) 5,000,000/QALY, i.e. JPY1,677,401/QALY and JPY1,351,811/QALY from payer and societal perspectives, respectively. PCV20 was dominant (less costly and more effective) compared with PPSV23. In local-level analysis, the introduction of PCV20 required initial costs but resulted in greater cost savings related to medical expenses (-JPY424 and -JPY430 per person) and nursing care (-JPY560 and -JPY575 per person) compared to PPSV23 and no vaccination, respectively.

Conclusions: PCV20 is cost-effective compared with PPSV23 and no vaccination in adults aged 66-84 years, which could reduce the future healthcare burden in Japan.

查看原文本刊更多论文

20价肺炎球菌结合疫苗对日本和滋贺县66-84岁成人的健康和经济影响

背景：日本国家肺炎球菌病免疫规划（PD）包括23价肺炎球菌多糖疫苗（PPSV23），但不为≥66岁的成年人提供疫苗接种。我们评估了日本66-84岁无PPSV23疫苗接种史的成人接种20价肺炎球菌结合疫苗（PCV20）的成本效益，并评估了引入PCV20对当地政府（特别是滋贺县）的潜在经济和健康影响。研究设计和方法：使用马尔可夫模型，我们评估了终身成本、质量调整生命年（QALYs）以及PD引起的预防病例数和死亡人数。结果：在国家层面的分析中，在500万日元/QALY的增量成本-效果比阈值下，PCV20与未接种相比具有成本效益，分别为1,677,401日元/QALY和1,351,811日元/QALY。与PPSV23相比，PCV20占主导地位（成本更低，更有效）。在地方一级的分析中，与PPSV23和未接种疫苗相比，PCV20的引入需要初始成本，但在医疗费用（每人- 424日元和- 430日元）和护理费用（每人- 560日元和- 575日元）方面节省了更多成本。结论：与未接种PPSV23的66-84岁成人相比，PCV20具有成本效益，可减轻日本未来的医疗负担。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.